Related Experiment Videos
MR techniques for in vivo molecular and cellular imaging
Edward J Delikatny1, Harish Poptani
1Molecular Imaging Laboratory, Department of Radiology, University of Pennsylvania School of Medicine, B6 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA. delikatn@mail.med.upenn.edu
Radiologic Clinics of North America
|February 8, 2005
Summary
Magnetic resonance (MR)-based molecular imaging is emerging, with new targeted contrast agents crucial for future clinical applications. Overcoming sensitivity and specificity challenges will enhance MR
Area of Science:
- Molecular imaging
- Magnetic Resonance (MR) imaging
- Biomedical engineering
Background:
- Current MR contrast agents primarily assess gross physiological function, not specific biochemical pathways.
- The development of targeted, smart contrast agents for clinical use is in its early stages.
- MR imaging offers high resolution and simultaneous structure/function assessment, positioning it for future molecular imaging roles.
Purpose of the Study:
- To highlight the pivotal role of MR imaging in the future of clinical molecular imaging.
- To discuss the development and challenges of targeted, smart contrast agents for MR-based molecular imaging.
- To explore strategies for overcoming MR imaging's sensitivity and specificity limitations.
Main Methods:
- Review of current contrast agent technology and limitations.
- Discussion of requirements for novel smart contrast agents, including toxicity and pharmacokinetic assessments.
- Exploration of signal amplification techniques (high relaxivity, superparamagnetic particles) and relaxivity modulation.
- Consideration of spectroscopic property changes for enhanced discrimination.
Main Results:
- MR imaging's high resolution and functional assessment capabilities are key to its future in molecular imaging.
- Development of smart contrast agents is paramount for monitoring biological processes like receptor function and gene expression.
- Signal amplification and relaxivity modulation show promise for improving sensitivity and target specificity.
- Integration of spectroscopic imaging offers further discrimination capabilities.
Conclusions:
- MR-based molecular imaging holds significant future potential, driven by advancements in targeted contrast agents.
- Overcoming challenges in sensitivity and specificity is critical for clinical translation.
- Novel contrast agent designs, including signal amplification and spectroscopic indicators, will enhance MR's discriminative power.
- Rigorous testing and validation are essential for the clinical approval of new MR molecular imaging agents.